Evidence map›Paper›PMID 33574231›Full record

ArticleBlood cancer journal2021

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.

Konstantinos Liapis, Vasileios Papadopoulos, George Vrachiolias, Athanasios G Galanopoulos, Menelaos Papoutselis, Sotirios G Papageorgiou, Panagiotis T Diamantopoulos, Vassiliki Pappa, Nora-Athina Viniou, Alexandra Kourakli and 18 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 15 institutions in 1 country.

Konstantinos LiapisDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece. kosliapis@hotmail.com.ORCID 0000-0003-1165-9639
Vasileios PapadopoulosDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.ORCID 0000-0002-4188-9518
George VrachioliasDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.
Athanasios G GalanopoulosDepartment of Clinical Hematology, Georgios Gennimatas Hospital, Athens, Greece.
Menelaos PapoutselisDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.
Sotirios G PapageorgiouSecond Department of Internal Medicine, Attikon University General Hospital, Athens, Greece.
Panagiotis T DiamantopoulosFirst Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Vassiliki PappaSecond Department of Internal Medicine, Attikon University General Hospital, Athens, Greece.
Nora-Athina ViniouFirst Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Alexandra KourakliGreece Department of Internal Medicine, University Hospital of Patras, Rio, Greece.
Dimitris ΤsokanasDepartment of Clinical Hematology, Georgios Gennimatas Hospital, Athens, Greece.
Theodoros P VassilakopoulosDepartment of Hematology, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Eleftheria HatzimichaelDepartment of Hematology, University Hospital of Ioannina, Ioannina, Greece.ORCID 0000-0002-4408-5646
Eleni BouronikouDepartment of Hematology, University Hospital of Larissa, Larissa, Greece.
Maria XimeriDepartment of Hematology, University General Hospital of Heraklion, Voutes, Heraklion, Greece.
Charalambos PontikoglouDepartment of Hematology, University General Hospital of Heraklion, Voutes, Heraklion, Greece.
Aekaterini MegalakakiDepartment of Hematology, Metaxa Oncology Hospital, Piraeus, Greece.
Panagiotis ZikosDepartment of Hematology, Aghios Andreas General Hospital, Patras, Greece.
Panayiotis PanayiotidisFirst Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Maria DimouFirst Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0001-8197-9895
Stamatis KarakatsanisDepartment of Hematology, Sotiria General Hospital, Athens, Greece.ORCID 0000-0003-1793-6617
Maria PapaioannouDepartment of Hematology, AHEPA University Hospital, Thessaloniki, Greece.
Anna VardiDepartment of Hematology and Stem cell Transplantation, Georgios Papanicolaou General Hospital, Thessaloniki, Greece.
Flora KontopidouSecond Department of Internal Medicine, National and Kapodistrian University of Athens, Hippokratio General Hospital, Athens, Greece.
Nikolaos HarchalakisDepartment of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece.
Ioannis AdamopoulosDepartment of Hematology and Thalassemia, Kalamata General Hospital, Kalamata, Greece.
Argiris SymeonidisGreece Department of Internal Medicine, University Hospital of Patras, Rio, Greece.ORCID 0000-0002-3685-3473
Ioannis KotsianidisDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.
National and Kapodistrian University of Athens · GRDemocritus University of Thrace · GRGeneral Hospital of Athens G. Genimatas · GRGeneral University Hospital of Patras · GRUniversity General Hospital Attikon · GRUniversity Hospital of Heraklion · GRAgios Andreas Hospital · GRAHEPA University Hospital · GREvangelismos Hospital · GRGeneral Hospital of Drama · GRG. Papanikolaou General Hospital · GRMetaxa Hospital · GRSotiria General Hospital · GRUniversity Hospital of Ioannina · GRUniversity Hospital of Larissa · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overAntimetabolites, AntineoplasticAzacitidineFemaleFollow-Up StudiesHumansMaleMiddle AgedMyelodysplastic SyndromesPrognosisRisk FactorsSurvival AnalysisAntimetabolites, AntineoplasticAzacitidine

Identifiers

PMID33574231
PMCPMC7878783
OpenAlexW3127316903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.